Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€2.79

€2.79

0.430%
0.012
0.430%
-

-

 
17:07 / Tradegate WKN: A1J643 / Name: Puma Biotechnology / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
28.11.21
-2.48%
buy
13.03.21
-71.12%
buy
Your prediction

Puma Biotechnology Inc. Stock

The Puma Biotechnology Inc. stock is trending slightly upwards today, with an increase of €0.012 (0.430%) compared to yesterday's price.
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Puma Biotechnology Inc. stock is not clear.

Pros and Cons of Puma Biotechnology Inc. in the next few years

Pros
?
Brand
?
Market Position
?
Shareholder structure
Cons
?
Growth compared to competition
?
Conscious of the environment
?
Worthwhile Investment for the next years
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Puma Biotechnology Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Puma Biotechnology Inc. 0.430% -8.165% -39.818% -69.745% -66.392% - -
Clovis Oncology Inc. -1.740% -4.301% -23.385% -27.434% -21.262% -80.634% -91.630%
Champions Oncology Inc 3.870% - - - - - -
Aveo Pharmaceuticals Inc. -1.220% -4.500% -1.207% 28.764% 28.331% -68.689% -6.678%

Other discussions about Puma Biotechnology Inc. Stock

New thread Forum

News

Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) issued a Patent Term Extension Certificate for U.S. Patent

Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that investigators presented results from the neratinib arm of the Phase II Individualized Screening Trial of

Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 9 abstracts that will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS), to be held